Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Deferred Taxes (2016 - 2017)

Historic Deferred Taxes for CytomX Therapeutics (CTMX) over the last 3 years, with Q4 2017 value amounting to -$520000.0.

  • CytomX Therapeutics' Deferred Taxes changed N/A to -$520000.0 in Q4 2017 from the same period last year, while for Dec 2017 it was -$513000.0, marking a year-over-year decrease of 865000.0%. This contributed to the annual value of -$513000.0 for FY2017, which is 865000.0% down from last year.
  • According to the latest figures from Q4 2017, CytomX Therapeutics' Deferred Taxes is -$520000.0.
  • CytomX Therapeutics' Deferred Taxes' 5-year high stood at $25000.0 during Q2 2017, with a 5-year trough of -$520000.0 in Q4 2017.
  • Over the past 3 years, CytomX Therapeutics' median Deferred Taxes value was $3000.0 (recorded in 2015), while the average stood at -$72000.0.
  • The largest annual percentage gain for CytomX Therapeutics' Deferred Taxes in the last 5 years was 73333.33% (2017), contrasted with its biggest fall of 6666.67% (2017).
  • Quarter analysis of 3 years shows CytomX Therapeutics' Deferred Taxes stood at $3000.0 in 2015, then changed by 0.0% to $3000.0 in 2016, then plummeted by 17433.33% to -$520000.0 in 2017.
  • Its last three reported values are -$520000.0 in Q4 2017, -$19000.0 for Q3 2017, and $25000.0 during Q2 2017.